enVVeno Medical Corp (NASDAQ:NVNO)
| Market Cap | $3.65M-57.2% |
| Revenue (ttm) | $0 |
| Net Income | -$15.55M+29.2% |
| EPS | -$22.38+81.7% |
| Shares Out | 694.83K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,355 |
| Open | $5.53 |
| Previous Close | $5.57 |
| Day's Range | $5.22 - $5.76 |
| 52-Week Range | $5.22 - $14.89 |
| Beta | 1.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 25, 2027 |
About NVNO
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 25, 2027Earnings report
$NVNO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NVNO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NVNO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NVNO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NVNO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NVNO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NVNO
| VXFVanguard Extended Market ETF | $42.31K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NVNO’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 15Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
